Acquiring Akero Therapeutics for $54 / shr
• $4.7bn upfront. Note that Akero had $1bn cash on the balance sheet which mitigates the deal cost.
• Further entitlements to $0.5bn upon US approval for etruxifermin (EFX).
• Gives Novo access to EFX - a treatment for metabolic dysfunction-associated steatohepatitis (MASH).
• MASH is a leading cause of obesity comorbidity.
• Akero currently has zero revenue.
• Net cost of $3.7bn is only 0.2x EBITDA.
Find more articles and bullets on these widgets:
| Type | 8-month RFTB | 11-month RFTB |
| Maturity | May 13, 2026 | Aug 13, 2026 |
| Amount | E1.036bln | E965mln |
| Target | E2.0bln | Shared |
| Previous | E1.17bln | E1.126bln |
| Avg yield | 1.98% | 1.99% |
| Previous | 1.966% | 1.907% |
| Bid-to-cover | 1.87x | 2.03x |
| Previous | 1.80x | 1.67x |
| Previous date | Aug 05, 2025 | Jun 03, 2025 |
Source: Bloomberg
The implied probability of a government shutdown on October 1 receded slightly after appropriators huddled yesterday for a bipartisan and bicameral meeting to discuss the funding deadline.
Figure 1: Government Shutdown by October 1 
Source: Polymarket